Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « fibrosis »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
fibrosing < fibrosis < fibrotic  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000001 (2020) A. Prasse [Allemagne] ; F. Bonella [Allemagne] ; U. Müller-Ladner [Allemagne] ; T. Witte [Allemagne] ; N. Hunzelmann [Allemagne] ; J. Distler [Allemagne][Treatment of systemic sclerosis-associated interstitial lung disease].
000003 (2020) Charlotte Girard-Guyonvarc'H ; Michele Iudici[Targeted therapies for connective tissue diseases and vasculitis].
000074 (2020) Grégoire Ducoux [France] ; Arthur Guerber [France] ; Cécile-Audrey Durel [France] ; Bouchra Asli [France] ; Jehane Fadlallah [France] ; Arnaud Hot [France]Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients
000125 (2020) Gali Epstein Shochet [Israël] ; Elizabetha Brook [Israël] ; Becky Bardenstein-Wald [Israël] ; David Shitrit [Israël]TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
000213 (2020) Ludivine Renaud [États-Unis] ; Willian A. Da Silveira [Royaume-Uni] ; Naoko Takamura [États-Unis] ; Gary Hardiman [États-Unis, Royaume-Uni] ; Carol Feghali-Bostwick [États-Unis]Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis
000214 (2020) Alyson W. Wong [Canada] ; Christopher J. Ryerson [Canada] ; Sabina A. Guler [Suisse]Progression of fibrosing interstitial lung disease
000233 (2020) Giulia Cassone [Italie] ; Marco Sebastiani [Italie] ; Caterina Vacchi [Italie] ; Stefania Cerri [Italie] ; Carlo Salvarani [Italie] ; Andreina Manfredi [Italie]Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
000242 (2020) Colin H. Holtze [États-Unis] ; Elizabeth A. Freiheit [États-Unis] ; Susan L. Limb [États-Unis] ; John L. Stauffer [États-Unis] ; Karina Raimundo [États-Unis] ; Wayne T. Pan [États-Unis] ; Kevin R. Flaherty [États-Unis] ; Hyun J. Kim [États-Unis]Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
000311 (2020) Durga Prasanna Misra [Inde] ; Sakir Ahmed [Inde] ; Vikas Agarwal [Inde]Is biological therapy in systemic sclerosis the answer?
000327 (2020) Jakob Einhaus [Allemagne] ; Ann-Christin Pecher [Allemagne] ; Elisa Asteriti [Allemagne] ; Hannes Schmid [Allemagne] ; Kathy-Ann Secker [Allemagne] ; Silke Duerr-Stoerzer [Allemagne] ; Hildegard Keppeler [Allemagne] ; Reinhild Klein [Allemagne] ; Corina Schneidawind [Allemagne] ; Joerg Henes [Allemagne] ; Dominik Schneidawind [Allemagne]Inhibition of effector B cells by ibrutinib in systemic sclerosis
000349 (2020) Benjamin Corden ; Eleonora Adami ; Mark Sweeney ; Sebastian Schafer ; Stuart A. CookIL‐11 in cardiac and renal fibrosis: Late to the party but a central player
000353 (2020) Tian-Yu Lin ; Yu-Hsiang Hsu [Taïwan]IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target
000393 (2020) Dinesh Khanna ; Donald P. Tashkin ; Christopher P. Denton ; Elisabetta A. Renzoni ; Sujal R. Desai ; John VargaEtiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
000411 (2020) Lutz Wollin [Allemagne] ; Dieudonnée Togbe [France] ; Bernhard Ryffel [France]Effects of Nintedanib in an Animal Model of Liver Fibrosis
000559 (2020) Henning Ulrich [Brésil] ; Micheli M. PillatCD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
000622 (2016) Yannick Allanore [France]Physiopathologie de la sclérodermie systémique

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "fibrosis" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "fibrosis" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    fibrosis
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021